Lördag 21 December | 16:46:50 Europe / Stockholm

Kalender

Tid*
2025-08-12 08:00 Kvartalsrapport 2025-Q2
2025-03-06 N/A Årsstämma
2025-02-05 07:30 Bokslutskommuniké 2024
2024-08-14 - Kvartalsrapport 2024-Q2
2024-03-07 - X-dag ordinarie utdelning DEMANT 0.00 DKK
2024-03-06 - Årsstämma
2024-02-06 - Bokslutskommuniké 2023
2023-08-15 - Kvartalsrapport 2023-Q2
2023-03-09 - X-dag ordinarie utdelning DEMANT 0.00 DKK
2023-03-08 - Årsstämma
2023-02-07 - Bokslutskommuniké 2022
2022-08-16 - Kvartalsrapport 2022-Q2
2022-03-11 - X-dag ordinarie utdelning DEMANT 0.00 DKK
2022-03-10 - Årsstämma
2022-02-08 - Bokslutskommuniké 2021
2021-08-12 - Kvartalsrapport 2021-Q2
2021-03-08 - X-dag ordinarie utdelning DEMANT 0.00 DKK
2021-03-05 - Årsstämma
2021-02-09 - Bokslutskommuniké 2020
2020-08-17 - Kvartalsrapport 2020-Q2
2020-03-11 - X-dag ordinarie utdelning DEMANT 0.00 DKK
2020-03-10 - Årsstämma
2020-02-04 - Bokslutskommuniké 2019
2019-08-14 - Kvartalsrapport 2019-Q2
2019-03-20 - X-dag ordinarie utdelning DEMANT 0.00 DKK
2019-03-19 - Årsstämma
2019-02-19 - Bokslutskommuniké 2018
2018-08-15 - Kvartalsrapport 2018-Q2
2018-03-23 - X-dag ordinarie utdelning DEMANT 0.00 DKK
2018-03-22 - Årsstämma
2018-02-22 - Bokslutskommuniké 2017
2017-08-14 - Kvartalsrapport 2017-Q2
2017-05-09 - Kvartalsrapport 2017-Q1
2017-03-28 - X-dag ordinarie utdelning DEMANT 0.00 DKK
2017-03-27 - Årsstämma
2017-02-23 - Bokslutskommuniké 2016
2016-11-10 - Kvartalsrapport 2016-Q3
2016-08-17 - Kvartalsrapport 2016-Q2
2016-05-25 - Split DEMANT 1:5
2016-05-10 - Kvartalsrapport 2016-Q1
2016-04-08 - X-dag ordinarie utdelning DEMANT 0.00 DKK
2016-04-07 - Årsstämma
2016-03-01 - Bokslutskommuniké 2015
2015-11-12 - Kvartalsrapport 2015-Q3
2015-08-14 - Kvartalsrapport 2015-Q2
2015-05-07 - Kvartalsrapport 2015-Q1
2015-04-10 - X-dag ordinarie utdelning DEMANT 0.00 DKK
2015-04-09 - Årsstämma
2015-02-26 - Bokslutskommuniké 2014
2014-11-13 - Kvartalsrapport 2014-Q3
2014-08-14 - Kvartalsrapport 2014-Q2
2014-05-08 - Kvartalsrapport 2014-Q1
2014-04-10 - X-dag ordinarie utdelning DEMANT 0.00 DKK
2014-04-09 - Årsstämma
2014-02-27 - Bokslutskommuniké 2013
2013-11-05 - Kvartalsrapport 2013-Q3
2013-08-14 - Kvartalsrapport 2013-Q2
2013-05-07 - Kvartalsrapport 2013-Q1
2013-04-10 - X-dag ordinarie utdelning DEMANT 0.00 DKK
2013-04-09 - Årsstämma
2013-02-26 - Bokslutskommuniké 2012
2012-11-07 - Kvartalsrapport 2012-Q3
2012-08-16 - Kvartalsrapport 2012-Q2
2012-05-10 - Kvartalsrapport 2012-Q1
2012-04-12 - X-dag ordinarie utdelning DEMANT 0.00 DKK
2012-04-11 - Årsstämma
2012-02-29 - Bokslutskommuniké 2011
2011-11-10 - Kvartalsrapport 2011-Q3
2011-08-19 - Kvartalsrapport 2011-Q2
2011-05-12 - Kvartalsrapport 2011-Q1
2011-04-14 - X-dag ordinarie utdelning DEMANT 0.00 DKK
2011-04-13 - Årsstämma
2010-11-16 - Kvartalsrapport 2010-Q3
2010-04-08 - X-dag ordinarie utdelning DEMANT 0.00 DKK

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriMedicinteknik
Demant är verksamt inom medicinteknik. Bolaget är specialiserat inom utveckling av hörapparater och hörslingor. Idag innehar bolaget verksamhet på global nivå där produkterna säljs under varierande varumärken. Produkterna nås via bolagets distributörer och försäljningskanaler. Utöver huvudverksamheten bedriver bolaget forskning inom diagnostik för mätning av hörselkvalitén. Bolaget grundades ursprungligen under 1904 och har sitt huvudkontor i Smörum.
2024-09-16 10:30:09

16.9.2024 10:30:08 CEST | Demant A/S | Investor News

Investor news

16 September 2024

 

New President of Diagnostics and member of Demant Management

 

Effective 1 November 2024, Anne-Karen Hunt will join Demant and take up the position as President of Demant’s Diagnostics business area. René Schneider, who concurrently with his role as CFO of Demant, has held the position as interim President since April 2023, will help ensure a proper transition when Anne-Karen Hunt joins the company.

 

Anne-Karen Hunt has spent the last 20 years of her career in various international medical technology companies, most recently in GE HealthCare where she held the position as General Manager and President of the Ultrasound International business of the EMEA, APAC and LATAM regions.

 

Besides taking on the responsibility for the Diagnostics business area, Anne-Karen Hunt will join Demant Management and thus take part in driving Demant’s strategy forward.

 

“I am looking forward to welcoming Anne-Karen Hunt as new President of Diagnostics and member of the Demant Management. Anne-Karen Hunt is a strong profile and a strategic thinker, who has successfully led large, international organisations with a proven track record of business development and performance. She has a collaborative leadership mindset and focuses on creating trust in high-performing teams.

 

She is the right profile for leading our Diagnostics business area into the future, and I am sure she will do great things in collaboration with the many talented people in our Diagnostics business and across Demant,” says Søren Nielsen, President and CEO in Demant.

 

Anne-Karen Hunt is of German nationality. Her educational background is in marketing and economics, and she holds an MBA from the University of Düsseldorf.

 

“I am excited to join Demant. The combination of a company truly committed to hearing healthcare, a strong purpose of making life-changing differences and a long track record of profitable growth is very interesting to me. During my career, I have always been focused on understanding the customer needs as the foundation for building business strategy, and I look forward to getting to know the Diagnostics business further and contributing to its ongoing development and success,” says Anne-Karen Hunt.

 

Curriculum vitae – Anne-Karen Hunt

 

2023 – now:     GE HealthCare

  • General Manager and President – Ultrasound International (EMEA, APAC, LATAM)
  • General Manager and President – Imaging (EMEA)

 

2017-2023:      Abbott

  • Divisional VP Commercial – Abbott Cardiac Rhythm Management (EMEA)
  • Divisional VP Commercial – Abbott Heart Failure (AMERICAS)
  • International Head & General Manager – Neuromodulation (EMEA & APAC)

 

2002-2017:      Various positions with Terumo Interventional Systems and Johnson & Johnson

Further information:

Søren Nielsen, President & CEO

Phone +45 3917 7300

www.demant.com

Other contacts:

René Schneider, CFO

Peter Pudselykke, Head of Investor Relations

Henrik Axel Lynge Buchter, Manager of External Communications

 

About Demant A/S

Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect with the world around them. In every aspect, from hearing devices, hearing implants, diagnostics to audio and video solutions and hearing care all over the world, Demant is active and engaged. Our innovative technologies and know-how help improve people’s health and hear-ing. We create life-changing differences through hearing health.

Attachments